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Familial Colorectal Cancer Type X (FCCTX) is a type of
hereditary nonpolyposis colorectal cancer in accordance to
Amsterdam criteria-1 for Lynch syndrome, with no related
mutation in mismatch repair gene. FCCTX is microsatellite
stable and is accounted for 40% of families with Amsterdam
criteria-1 with a high age of onset. Thus, the carcinogenesis
of FCCTX is different compared to Lynch syndrome. In
addition to the microsatellite stability and the presence of
less predominant tumors in proximal colon, various clinical
features have also been associated with FCCTX in compar-
ison with Lynch syndrome such as no increased risk of extra-
colonic cancers, older age of diagnosis and higher adenoma/
carcinoma rate. Genetic etiology of this type of cancer which
is autosomal dominant is unknown. In this review, we focus
on the genes and their variants identiﬁed in this type of CRC.
In order to ﬁnd out the correlation between FCCTX and
various genes database such as PubMed and PMC, search
engine such as Google scholar and portals such as Springer
and Elsevier have been searched. Based on our literature
search, several studies suggest that FCCTX is a heteroge-
neous type of disease with different genetic variants. Recent
studies describe the correlation between FCCTX and genes002
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APC, BMPR1A, and RPS20. Considering the fact that BRCA2 has
the highest mutation rate (60%) and is one of the most
crucial DNA repair genes, it will be considered as a big role
player in this type of cancer in comparison with other genes.
& 2017 Elsevier Inc. All rights reserved.Introduction
Among patients with clinical characteristics of hereditary nonpolyposis colorectal cancers (CRCs),
there is a group known as Familial Colorectal Cancer Type X (FCCTX)1 which is deﬁned based on
Amsterdam Criteria-1 (AC1) for Lynch syndrome.2 Among this type of CRCs, 40% of families met AC1
criteria.3 Since this type of cancer has no mutation in mismatch repair gene (MMR), the tumors have
been characterized as microsatellite stable.4 Thus, the carcinogenesis of FCCTX is different compared
to Lynch syndrome.5,6
In addition to the microsatellite stability and the presence of less predominant tumors in
proximal colon, various clinical features have also been associated with FCCTX in comparison
with Lynch syndrome such as no increased risk of extra-colonic cancers, older age of diagnosis,
and higher adenoma/carcinoma rate.3,7-9 Despite the recent progress in clinical detection of
FCCTX, its genetic etiology has remained unknown.3 FCCTX may be resulted from more than one
genetic etiology.2 Different studies suggest that FCCTX is a heterogeneous disease with various
clinical variants.10 Detection of the genes associated with FCCTX will facilitate the molecular
diagnosis of the disease.4,9,11 Current evidence shows that FCCTX families constitute a high
heterogeneous group. In this review, we focus on the genes and their variants identiﬁed in this
type of CRC.
The literature review has been performed in order to ﬁnd out the correlation between FCCTX and
various genes. Only studies published in English were included. Keywords such as “FCCTX” and
“genes” have been used to search for all articles related to genetic basis of FCCTX.
In this review, we have searched the most recent published articles. Retrieved articles had
original contributions or were review articles.
For each study, the following action was performed: collecting information about the numbers of
cases and controls, the genes involved, type of mutations, mutation frequency rate, and the type of
analyzing process (for instance, linkage analysis or any other studies).The important inclusion factor
was fulﬁlling Amsterdam criteria. Then all related articles were collected, the results were analyzed
and a comparison was made between various genes.Genes
BRCA2 gene
BRCA2 gene has high tumor heterogeneity and it is a good candidate for FCCTX.12 Some studies
show the relation between rare BRCA2 alleles and CRC13 and the linkage between a marker in
BRCA2 gene and familial colorectal families.14 In addition, in recent studies on 48 FCCTX families,
27 coding sequences and intron/exon boundaries in BRCA2 gene were analyzed and 29 BRCA2
variants including 28 point mutations (14 missense, 12 silent, and 2 intronic) and 1 frameshift
mutation were found. The most striking result of this work was the frameshift mutation
c.3847_3848delGT p. (Val1283Lysfs*2) detected in 1 FCCTX family. In this family, 1 breast cancer,
4 CRCs, and 1 prostate cancer in 2 following generations have been found.12 Val1283Lysfs*2
mutation is reported in the Breast Cancer Information Core database as pathogenic mutation for
Hereditary Breast and Ovarian Cancer Syndrome (HBOC) and it has also been observed in prostate
cancer.15
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p.(Pro168Thr), c.502C4A, c.5744C4T p.(Thr1915Met), c.927A4G p.(Ser309¼), and c.7759C4T
p.(Leu2587Phe), which could act as predisposition alleles in these families.12
SEMA4A gene
SEMA4A is a membrane-bound class 4 semaphorin receptor family,16-18 Semaphorins, function-
ally act in physiological and developmental procedures; additionally an association between
semaphorins and their receptors with malignant disorders has been found.19,20 Recent study on
Austrian patients with FCCTX shows that only variant p.val78met of this gene could be observed in
all patients. When samples were analyzed for copy-number alterations, they observed ampliﬁcation
on SEMA4A locus.21 In comparison with wild-type protein, clinical variant V78M shows highly
related to activated MAPK/Erk and PI3K/Akt signaling pathway. Inheritance pattern of the germline
variant V78M was autosomal dominant with incomplete penetrance.21 In this variant, tumor
development occurred at a higher age compared to the patients affected with classical Lynch
syndrome. In this study and in 53 FCCTX patients, 2 more SEMA4A mutations, p.Gly484Ala and
p.Ser326Phe have been found. Also, the single nucleotide polymorphism (SNP) p.Pro682Ser has been
detected. This single nucleotide polymorphism is highly related to the FCCTX phenotype showing
enhanced risk of CRC.
Additional genetic factors, environmental parameters and lifestyle modiﬁers are necessary to
establish the malignant phenotype. Such a genetic modiﬁer might be MUTYH where the
heterozygous germline variant R217H was found in 2 V78M carriers affected by CRC.22
KRAS gene
In a study by Sanchez-de-Abajo et al, performed on 28 tumors dissected from 17 different
families affected with FCCTX, genetic analysis of KRAS shows that the mutation rates are similar to
Lynch syndrome and sporadic CRCs. These mutations were disproportionately in codon 12 compared
to equal representation between codons 12 and 13 in Lynch syndrome.23 Also in a study performed
by Sánchez-Tome et al24 on 22 FCCTX affected families, mutational analysis of KRAS show variants
that was similar to the above-mentioned ﬁndings. But in another study by Francisco et al25 on 15
FCCTX families, mutational analysis of exon 2 in KRAS gene, show KRAS somatic mutations in 11/24
(46%) of the FCCTX tumors. Also FCCTX tumors showed the highest frequency of mutations in codon
12 (ie, 91%) compared to Lynch syndrome or sporadic MSI-H tumors.25
BRAF gene
In addition to the above-mentioned mutations, in a study by Sanchez-de-Abajo et al23 similar
mutation in KRAS and BRAF has also been found in 3.6% of patients, and was not different from Lynch
syndrome and sporadic CRCs. Thus, between the Type X families and the sporadic microsatellite-
stable cancer, the changes in the RAS/RAF signaling pathway appeared similar, leading the authors to
propose that some Type X families are classiﬁed as such due to the chance of aggregation of sporadic
cases.1 Similarly, in the Sánchez-Tome et al study, in all FCCTX tumors screened for BRAF mutations,
high-resolution melting analysis has been used to ﬁnd the mutations on exon 15 of the gene
(including the hotspot V600E).23 BRAF mutations were identiﬁed in 3 out of 23 tumors and again it
was shown that BRAF mutations are similar to those described for CRC in general.26
APC gene
The situation of APC gene is like 2 other genes including KRAS and BRAF.27 However in a study by
Francisco et al,25 in order to detect somatic mutations in exon 15 of APC, the mutation cluster region
was examined by automated sequencing. They found the p.E1317Q mutation in 1 out of 10 tumor
suppressor gene (TSG) which correlate to loss of function and all the affected relatives were positive
for the germline missense mutation. Also they identiﬁed truncated APC somatic mutations in (39%
of) tumors. Loss of heterozygosity (LOH) of the APC locus was found in 42% of tumors that resulted in
the detection of APC somatic mutations (either truncated mutations or LOH) in 15/24 (62%) of the
FCCTX tumors. Four missense mutations (p.E1353D, p.E1374K, p.Q1429H, and p.N1473T) were also
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combination with LOH.28
MMR and MGMT genes
In the study by Francisco et al25 in 18 colorectal samples including 7 adenomas and 11
carcinomas from the FCCTX families, promoter methylation analysis of DNA repair genes using the
methylation-speciﬁc multiplex ligation-dependent probe ampliﬁcation was performed. While
hypermethylation of at least 1 of the MMR genes was observed in about 28% of the cases, MGMT
hypermethylation was found in 44% of FCCTX tumors. ForMGMT, hypermethylation (either ofMGMT
or MMR genes) appeared to be more common among TSG loss positive tumor in comparison to the
TGS loss negative group, and in the case of the MMR genes, none of the TGS loss negative tumors
presented methylation.25,29 Interestingly, Francisco et al could also ﬁnd that the type of KRAS
mutations differed according to the MGMT methylation status so that C-T transitions were
signiﬁcantly more frequent among MGMT methylated tumors compared to the unmethylated ones.
BMPR1A gene
BMPR1A encodes a type I bone morphogenetic protein receptor that belongs to a family of serine/
threonine kinases.30 Earlier studies have proven that BMPR1A mutations are the cause of 20% of
juvenile polyposis syndrome and 50% of hereditary mixed polyposis syndrome in families.31,32 In a
study, 18 families from the Hereditary Colorectal Cancer Registry of Finland, all fulﬁlling the AC1 and
having no MMR defects in tumor tissue or in the germline were investigated by genetic linkage
analysis, mutation analysis of candidate genes, and by molecular studies of tumor tissues.33
Genotyping with microsatellite markers resulted in a high limit of detection score for marker
D10S1686 residing on 10q23 locus. All 11 exons and the intron-exon boundaries of BMPR1A were
sequenced. One individual revealed a germline mutation consisting of an in-frame deletion of
3 nucleotides (AGA) at 264 nucleotide position in exon 3 (c.264-266del, with p.Glu88del a predicted
protein), which cosegregated with colon carcinoma and/or adenoma in the family. Remaining
families were screened for BMPR1A alterations, a splice site mutation (c.68-10_6814del) was found
in 1 family. The overall frequency of pathogenic BMPR1A mutations was 2/18 families (11%).
Patients in 2 families were examined and it was documented that the rate of polyps did not
fundamentally differ from typical screening consequences of MMR gene mutation-positive patients
in Lynch syndrome. No juvenile polyps, polyps with mixed histology, serrated adenomas, or sessile-
serrated polyps/adenomas were identiﬁed.33,34
RPS20 gene
In a study by Nieminen et al35 performed on 26 FCCX families, genetic linkage analysis, exome
sequencing, tumor studies, and functional investigations of 4 generations of a FCCTX family led to
the identiﬁcation of a truncated germline mutation in RPS20, which encodes a component (S20) of
the small ribosomal subunit and is a new colon cancer predisposition gene. Since this study was
subsequently in progress (in the recent study related to the role of BMPR1A gene in FCCTX), patients
with germline mutations in bone morphogenetic protein receptor type IA were omitted. A novel
germline mutation (c. 147 dupA) in the RPS20, was found in 7 CRC-affected patients. The mutation
leads to a frameshift and premature truncated protein (p.Val50SerfsX23) and was associated with a
defect in preribosomal RNA maturation. Their ﬁndings show that mutations in a gene encoding a
ribosomal protein can predispose individuals to microsatellite-stable colon cancer.35 The product of
RPS20 is required during the late steps of 18S ribosomal RNA (rRNA) formation.36 RPS20 encodes a
ribosomal protein with a component of the 40S subunit.35 When RPS20 function normally, it can
bind to Mdm2 and activate p53 tumors suppressor protein.37
Among 80 genes in the ribosomal protein gene family, at least 11 of them are recognized to be
mutated in Diamond-Blackfan anemia, a form of pure red cell aplasia that has a dominant pattern of
inheritance with some features like growth retardation and congenital anomalies. No such features
exist in colon cancer patients.38-40 It is shown that haploinsufﬁciency for RPS19 or RPS20 in mice play
a role in stabilizing p53,41 discoveries make them speculate that cell type-speciﬁc effects of RPS20
M. Nejadtaghi et al. / Current Problems in Cancer 41 (2017) 388–397392haploinsufﬁciency might have a function in RPS20-associated colon tumor formation in human
cancers.42
Unrelated genes
Although some studies have been performed on relation between BRCA2, SEMA4, KRAS, BRAF,
APC, BMPR1A, and RPS20 and FCCTX cancer, no speciﬁc variants have been discovered. Similarly,
about NTS gene, its variant does not demonstrate considerable difference comparing to normal
population.
NTS and RASSF9 gene
NTS (neurotensin) is a signiﬁcant regulatory hormone that affects many facets of gastrointestinal
role including motility, secretion, and mucosal growing. RASSF9 is a member of the family of RAS-
associated domain-containing proteins whose members have appropriate tumor suppressor roles.
A linkage analysis on 22 Spanish families affected with Lynch syndrome showed that 2p24.3, 4q13.1,
4q31.21, and 12q21.2-q21.31 loci are associated with FCCTX and a family-speciﬁc analysis approved a
better NPL-score for 12q21.2-q21.31.24 Eight (STR) markers within the 12q21.2-q21.31 were
genotyped; candidate causal genes were ampliﬁed by PCR and sequenced. Between more than 50
genes at 12q21 locus, RASSF9, and NTS have been chosen as the best candidates because of their
potential involvement in carcinogenesis and colorectal epithelium development.43-48 Both genes
were sequenced in all affected members, 2 variants were found in NTS gene in 2 families including a
missense mutation in exon 2 and a deletion in 3′-UTR region but no variants were found in RASSF9
gene.45 Nevertheless, the frequency that was detected in controls, in addition to an in silico study,
ruled out a probable deleterious effect for both genes.49-51
GALNT12 gene
GALNT12 encodes a key enzyme that has a function in the ﬁrst step of mucin type
O-glycosylation, this gene deﬁned as a candidate gene for hereditary CRC but not speciﬁcally for
FCCTX based on genomewide association studies. This gene is located in 9q22-33 near to a CRC
linkage pick and germline missense variants that decrease the enzymatic activity of the protein and
have been identiﬁed in CRC patients. Seguí et al52 sequenced coding regions of the gene in 103
probands, but they found no functionally relevant mutations. This shows that GALNT12 is a major
CRC susceptibility gene but it is not a major contributor of FCCTX.
Complementary studies
In this section, we review more studies on FCCTX regarding its relation to other genes.
Dominguez-Valentin et al studied gene expression proﬁle of 37 FCCTX tumors. They found
upregulation of 1059 genes that a number of genes (n ¼ 16) including: GNAS, P2RY2, RAMP2, MC1R,
VIP, F2R, F2RL2, EDN1, GRM8, GNAZ, GNG11, GNG12, HCRT, and PTGER1 were associated with the
G-protein coupled receptor pathway. In addition, validation study using qRT-PCR was performed
using 5 genes associated with cancer, the results show increased expression of AXIN2 and MYC in
FCCTX tumors, reduced expression of NDUFA9 in these tumors (and also in sporadic MMR proﬁcient
tumors).53
There is also another alteration identiﬁed in FCCTX. For example in a study by Christina
Therkildsen et al, array-based comparative genomic hybridization was applied to 23 CRC tumors
with FCCTX. FCCTX tumors showed genomic complication with common gains on chromosomes 17,
19, and 20q and losses of 15, 8p, and 18 loci. Gains of genetic material in 2 distinct loci including
20q12-13.12 and 20q13.2-13.32, was observed in 65% of the FCCTX tumors. Gain on chromosome
20q and loss on chromosome 18 notably differentiated CRCs associated with FCCTX from Lynch
syndrome.54
Some studies show that in these families 2 single molecular pathways are involved. In one of
them there is no TSG, loss of genes loci, and promoter methylation, in other pathway there is such an
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APC, and MGMT promoter methylation.25
In a recent study, Villacis et al assessed copy-number variations (CNVs) in 45 separate FCCTX
patients. By analyses with 2 different microarray platforms, they revealed 35 rare CNVs covering 67
known genes in 22 patients. They found gains (GALNT6 and GALNT11) and losses (SEMA3C) including
the same gene families related to CRC predisposition among the rare CNVs. By segregation analysis
performed on 4 relatives from 1 family, they suggested the involvement of GALNT11 and KMT2C in
those at risk of developing CRC.55
Other studies showed the association of hypomethylation in long interspersed nucleotide
element-1 (LINE-1) with familial CRC, including FCCTX.56,57 In addition in recent studies candidate
genes have been suggested, such as CENPE, CDH18, GREM1, BCR, KIF24, ZNF367, HABP4, GABBR2, and
BMP4.58
Also in the above-mentioned study by Melas et al59 in addition to APC, germline exome
sequencing was performed on DNA samples from 41 patients with FCCTX and a mutation in MSH6
was found.
Furthermore, it is documented that there is a phenotypic overlap between FCCTX and other
identiﬁed genetic syndromes such as PPAP (Polymerase proofreading associated polyposis)
syndrome in which the exonuclease domain of POLE (encoding DNA polymerase ε) or POLD1
(encoding DNA polymerase δ1) is mutated in the germline.60-62
There is an association between CRC and coronary artery disease and both probably develop
through common risk factors such as chronic inﬂammation mechanisms.63 For example Runt-
related transcription factor 2 (RUNX2) as a transcription factor, was detected in the nuclei of the
colon carcinoma cells.64 This transcription factor is mainly associated with osteogenesis and
osteogenesis is mediated by oxidative stress.65-67Results
Although the number of papers used in this review are adequate, but majority of them just study
the clinical differences between Lynch syndrome and FCCTX, and among these articles a limited
numbers potentially could help us about genetic basis of FCCTX. Almost 12 genes were studied in all
of these papers where the mutations of 10 genes and hypermethylation of 2 genes were addressed.
In the newest study in 2015, BRCA2 mutations were considered in FCCTX so we concluded that
BRCA2 gene probably has a signiﬁcant role in genetic basis of FCCTX in comparison to other genes.
According to other articles based on the mutation frequency rate, KRAS, APC, NTS, BRAF, BMPR1A, and
RPS20 are associated with FCCTX. Hypermethylation of MMR and MGMT also should not be ignored.
The Table describes the name of gene, the number of patients examined for each gene in the
literature and the frequency rate of each mutation. Also in the Figure a comparison between the
frequency rates of mutations found for each gene is presented.Discussion
FCCTX is a type of HNPCC in which tumors are microsatellite stable with no MMR-related
mutations. Genetic factors have an important function in CRC susceptibility, although the heritability
of this tumor is almost 35%.68 The lifetime risk of CRC is 5%-6%, deﬁned as without personal history
or family history of CRC and above the age of 50.69 Even though the FCCTX is a relatively recent
notion, a short study has already recognized some clinical and molecular differences between FCCTX
families and those with a MMR deﬁcient system.4 Despite the fact that the clinical identiﬁcation of
FCCTX has improved in recent years, its genetic etiology remained unknown.3 The deﬁnition of
FCCTX is still controversial. Originally, FCCTX collectively describes cases of CRC that meet clinical
AC1, but whose tumors are MMR proﬁcient as assessed by microsatellite instability testing,4
however, some studies of FCCTX have also included AC2 families with MMR-stable tumors.25,34,53,54
The study by Nieminen et al35 was based on FCCTX families, which fulﬁlled the AC1/2 or the
Table
Summary of selected studies on FCCTX, including reported genes and variants. Frequency rate of each mutation is based
on the total number of patients examined
References Genes Cases Clinical variants and frequency rate (%)
Garre et al12 BRCA2 48 FCCTX probands 29 Variants: 28 point mutations
(14 missense, 12 silents, and 2 intronics) (58%)
1 Frameshift mutation (2%)
Sánchez-Tome et al24 NTS 22 FCCTX families Missense alteration in exon 2 (1.5%)
Deletion in the 3 UTR region (20%)
Sánchez-Tome et al24 RASSF9 22 FCCTX families No variant
Seguí et al52 GALNT12 103 probands No variant
Francisco et al25 KRAS 15 FCCTX families Somatic mutation in exon 2 (46%)
Somatic mutation in exon 12 (91%)
Sánchez-Tome et al24 BRAF 23 Tumors 15 Exon mutation (13%)
Francisco et al25 APC 15 FCCTX families Mutation (39%)
LOH (62%)
Francisco et al25 MMR and MGMT 15 FCCTX families Promoter hypermethylation
MGMT (44%)
MMR (28%)
Nieminen et al33 BMPR1A 18 FCCTX families Overall frequency of pathogenic BMPR1A
mutations (11%)
Nieminen et al35 RPS20 26 FCCTX families Somatic mutation (7%)
Schulz et al21 SEMA4A 53 FCCTX patients Somatic mutations (2.7%)
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studies on genetic basis of FCCTX have been performed and different genes were introduced as
candidates for FCCTX. For instance in Garre et al12 study BRCA2 mutations were analyzed and 29
BRCA2 variants were found; including 28 point mutations and 1 frameshift mutation, or in another
study by Sánchez-Tome et al24 linkage analysis showed that 12q21.2-12q21.31 loci, is the regionwith
the highest NPL-score, and contains more than 50 genes that among them, RASSF9 and NTS were
considered good candidates. Both genes were sequenced in all affected members of the linked
families, and 2 variants in NTS gene were found. Similarly different studies on different genes have
been done. Based on these studies frequency of the mutation is 60% for BRCA2, 45.5% for KRAS, 39%
for APC, 21.5% for NTS, 13% for BRAF, 11% for BMPR1A, and 7% for RPS20. For RASSF9 gene, despite the
importance of the loci, no variant has been found, although this could be a remarkable clue for
focusing on other members of RASSF family and GALNT12. The methylation analysis of MGMT and
MMR shows the methylation rates of 44% and 28%, respectively. Considering the fact that BRCA2 gene
has high mutation rate of 60% and since it is one of the most crucial DNA repair genes, which its role
in different cancers is demonstrated in many articles, we could conclude that in comparison with60.0%
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Fig. Frequency rate of mutations found for each gene in FCCTX. (Color version of ﬁgure is available online.)
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genes, their importance has been evaluated based on frequency of mutations, the type of mutations,
and their effect that has on the protein function.
We have systematically reviewed the correlation between FCCTX and various related genes. The
good features of the present paper are the review of the related articles in the literature that
analyzed genetic basis of FCCTX. All candidate genes are collected in this article, thus for the
researchers it is a good opportunity to choose which gene could be the best one for the susceptible
cases. However this review has some limitations: for example since the molecular mechanism and
genetic basis of FCCTX are not well deﬁned, it is difﬁcult to choose a single gene as a deﬁnite
candidate. Moreover the future studies could clarify most of the complexities. It is likely that more
genes related to this syndrome will be found in the near future.
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